CD274 and esophageal squamous cell carcinoma: Across studies in untreated, advanced ESCC, we observed that the survival benefits of adding toripalimab to chemotherapy in JUPITER-06 were independent of PD-L1 expression level, results that were unique among the individual phase 3 studies in advanced ESCC.